• Single-center (Montefiore Medical Center, Bronx, NY, USA), retrospective chart analysis of 795 patients aged ≥18
    years with BMI >40 kg/m² (range 40-88) who were prescribed apixaban, rivaroxaban, or warfarin for VTE or AF*
    • Overall 2699 patients were identified; 1904 patients with VTE + AF, or indications for OAC other than VTE or AF
      were excluded
  • Measured recurrent VTE, stroke, and bleeding from the first Rx date (March 1, 2013-March 1, 2017) to the earliest of
    thrombotic event, medication d/c, death, or end of study (June 30, 2017)
  • Compared outcome rates using Pearson χ² or Fisher exact test; adjusted for differences in duration of follow-up via
    time-to-event analysis as well as differences in comorbidities, CHA2DS2-VASc score, and age where appropriate; and
    stratified analyses by OAC indication
  • Confirmed VTEs and strokes via review of imaging studies (e.g., compression ultrasonography, ventilation-perfusion
    scans, CT scans, and MRIs)
  • Measured safety as major bleeding and composite of major bleeding and CRNM bleeding per the Subcommittee on
    Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH
  • Documented INR of warfarin patients on the day of, or the day before if no INR was recorded on the day of the event,
    a thrombotic or bleeding event, capturing values >20 without the discrete values